Hepatopathy-Thrombocytopenia Syndrome During Actinomycin D Treatment May Be Related to MDR1 (ABCB1) Gene Polymorphisms

Başbınar Y., Amirfallah A., Çalıbaşı Koçal G., Olgun N.

AMERICAN JOURNAL OF THERAPEUTICS, vol.23, no.2, 2016 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 2
  • Publication Date: 2016
  • Doi Number: 10.1097/mjt.0000000000000020
  • Journal Name: AMERICAN JOURNAL OF THERAPEUTICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: actinomycin D, Wilms tumor, MDR1, ABCB1, hepatopathy-thrombocytopenia syndrome
  • Dokuz Eylül University Affiliated: Yes

Abstract

The antitumor agent actinomycin D has been used in the treatment of Wilms tumor for the past 40 years. Actinomycin D-induced hepatopathy-thrombocytopenia syndrome (HTS) is characterized as a rare syndrome. The mechanism underlying HTS may differ with individual multidrug resistance protein-1 (MDR1) genotype. The relationship between actinomycin D-related HTS and MDR1 gene mutations is presented in this case study of a pediatric patient with Wilms tumor. Our findings revealed that the girl had (-)1G>A, 1236C>T, 2677G>T, 3435C>T, and 61A>G MDR1 gene mutations. Understanding the function of genetic variants of MDR1 is an important aim for personalized cancer management.